Elucidating the specific pharmacological mechanism of motion (MOA) of naturally occurring compounds is often tough. While Tarselli et al. (60) made the main de novo synthetic pathway to conolidine and showcased that this Obviously occurring compound correctly suppresses responses to equally chemically induced and inflammation-derived pain, the phar